Trial Profile
An Open-label Multicenter Study on the Efficacy of Continuous Oral Dosing of Vemurafenib on Tumour Response in Previously Treated Patients With Metastatic Melanoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Vemurafenib (Primary)
- Indications Malignant melanoma
- Focus Registrational; Therapeutic Use
- Acronyms BRIM-2
- Sponsors Roche
- 27 Apr 2021 Results (N=898) of a pooled analysis of data from 3 studies BRIM-2, BRIM-3 and coBRIM study assessing relationship between vemurafenib exposure, as measured by the estimated apparent clearance at steady state and any grade more than or equal to 3 toxicity published in the Journal of Clinical Pharmacology
- 16 Aug 2019 Results of a pooled analysis of BRIM-2, BRIM-3, BRIM-7 and coBRIM studies assessing the impact of depth of response on survival in patients treated with cobimetinib +/- vemurafenib, published in the British Journal of Cancer
- 04 Jun 2019 Results of pooled analysis for patients treated with vemurafenib or cobimetinib plus vemurafenib in the BRIM-2, BRIM-3, BRIM-7, and coBRIM studies published in the European Journal of Cancer